Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AKER

Akers Biosciences (AKER) Stock Price, News & Analysis

Akers Biosciences logo

About Akers Biosciences Stock (NASDAQ:AKER)

Advanced Chart

Key Stats

Today's Range
$0.04
$0.05
50-Day Range
$2.47
$4.59
52-Week Range
$1.65
$6.97
Volume
71.27 million shs
Average Volume
769,876 shs
Market Capitalization
$804.34 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AKER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AKER Stock News Headlines

Washington prepares for war
While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.tc pixel
Cam Akers Not Worth A Look In Week 10
See More Headlines

AKER Stock Analysis - Frequently Asked Questions

Akers Biosciences, Inc. (NASDAQ:AKER) announced its quarterly earnings data on Thursday, November, 15th. The medical instruments supplier reported ($0.26) EPS for the quarter. The medical instruments supplier had revenue of $0.56 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akers Biosciences investors own include Sorrento Therapeutics (SRNE), Aytu BioPharma (AYTU), ImmunoGen (IMGN), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Vaxart (VXRT) and Neovasc (NVCN).

Company Calendar

Last Earnings
11/15/2018
Today
9/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
NASDAQ:AKER
CIK
1321834
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.89 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-87.42%
Return on Assets
-73.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.22
Quick Ratio
9.22

Sales & Book Value

Annual Sales
$1.58 million
Price / Sales
0.51
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.38 per share
Price / Book
0.01

Miscellaneous

Outstanding Shares
16,653,000
Free Float
N/A
Market Cap
$804.34 thousand
Optionable
Not Optionable
Beta
0.30
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:AKER) was last updated on 9/1/2025 by MarketBeat.com Staff
From Our Partners